Biocon is developing Insulin Tregopil, an oral prandial insulin tablet, for the treatment of type-1 and type-2 diabetes mellitus. The fast-acting oral insulin could improve post-prandial glucose control with reduced side effects and greater adherence, thus holding the promise to transform T1D management.  Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, is working toward bringing the first oral insulin product to the market, thus, providing a more convenient, effective, as well as a safer method for delivering insulin therapy.

1. INTRODUCTION

2. RESEARCH METHODOLOGY

3. MARKET INSIGHT

4. MARKET DYNAMICS

5. MARKET SEGMENTATION AND ANALYSIS

6. COMPANY PROFILES